Why the U.S. Neurology Clinical Trials Market Is Set to Nearly Double by 2034 — and What It Means for Pharma and CRO Leaders

With roughly 7 million Americans living with Alzheimer's disease alone, the pressure to bring new neurological therapies to market has rarely been higher — and the U.S. research infrastructure built to support that effort keeps expanding. According to Polaris Market Research, the U.S. Neurology Clinical Trials market was valued at USD 3.19 billion in 2024 and is projected to reach USD 6.07 billion by 2034, growing at a CAGR of 6.7% from 2025 to 2034, fueled by high disease prevalence and sustained government funding.

The Shift: What's Actually Changing in U.S. Neurology Trials

AI is moving from a buzzword to a working tool in U.S. trial design. Sponsors are using machine learning platforms to optimize protocols and shorten trial duration, natural language processing to extract insight from clinical notes and patient-reported outcomes, and predictive analytics layered on electronic health records to identify eligible candidates faster — all part of a broader market trend toward data-driven, faster-enrolling studies.

World-renowned institutions such as the Mayo Clinic, Cleveland Clinic, and Johns Hopkins give the U.S. an advantage few other countries can match: dedicated neurology departments, experienced investigators, and centralized health data that together let trials run faster and at a higher scientific standard, which continues to attract global sponsors looking to launch studies domestically.

U.S. Neurology Clinical Trials Market by the Numbers

• 2024 Market Size: USD 3.19 Billion
• 2025 Market Size: USD 3.40 Billion
• 2034 Projected Market Size: USD 6.07 Billion
• CAGR (2025–2034): 6.7%
• Largest Segment in 2024: Alzheimer's Disease (by Indication)

Growth Drivers, Key Players and Market Segments to Watch

Growth is being driven by the high prevalence of neurological disorders and sustained NIH funding through programs such as the BRAIN Initiative, with key players including IQVIA, ICON plc, Syneos Health, and Laboratory Corporation of America Holdings, alongside pharmaceutical sponsors such as Biogen, Pfizer, and Eisai, shaping the competitive landscape across segments such as By Phase, By Indication (Alzheimer's disease held the largest share in 2024), and By Value Chain, where CROs are the fastest-growing category.

The FDA's Fast Track, Breakthrough Therapy, and Orphan Drug designations continue to play a defining role in shaping where sponsors choose to run trials, cutting review timelines for serious or rare neurological conditions. Rising outsourcing to CROs is also reshaping the value chain, as companies look to manage multi-site trials, navigate FDA requirements, and integrate AI and digital monitoring tools without building all of that capability in-house.

Phase III Leads Today, but Observational Studies Are Catching Up Fast

Phase III trials currently command the largest share of U.S. neurology research spend, driven by a strong focus on late-stage validation ahead of FDA approval and the scale of patient populations required. Observational studies are closing the gap quickly, however, as healthcare systems, insurers, and regulators push for more real-world evidence on long-term outcomes — a trend supported by the country's extensive digital health records and patient registries.

👉 Want the full data behind this shift? Get a Free Sample Report → https://www.polarismarketresearch.com/industry-analysis/us-neurology-clinical-trials-market  

What This Means for Sponsors Evaluating U.S. Trial Sites and CROs

For sponsors and research teams evaluating U.S. trial sites and CRO partners, the underlying report breaks down company positioning, segment-level forecasts, and indication-level trends through 2034 — useful context for any site-selection, outsourcing, or regulatory-strategy conversation happening right now, especially as FDA fast-track programs continue to shape where and how quickly trials move toward approval.

Rising public awareness, driven by education campaigns and advocacy organizations, is also easing one of the industry's longest-standing pain points: recruiting enough patients for trials targeting rare or complex neurological conditions.

The Road Ahead

U.S. Neurology Clinical Trials Market Expect continued outsourcing to CROs as sponsors look to manage rising trial complexity and cost, alongside deeper integration of AI-based monitoring tools across multi-site studies. Alzheimer's disease should keep its position as the leading indication given sustained advocacy from groups such as the Alzheimer's Association and continued government funding, even as ALS and other rare-disease programs draw growing interest from biotech companies pursuing gene- and cell-therapy approaches.

With an aging population and a deep bench of research institutions, the U.S. is likely to remain the single largest neurology trial market in absolute dollar terms through 2034, even as sponsors increasingly weigh cost and speed advantages available in other regions for earlier-phase work.

More Trending Latest Reports By Polaris Market Research:

smart-indoor-gardening-system-market

apparel-and-footwear-market

regenerative-medicine-market

diagnostic-services-market

devops-market

tile-stone-adhesive-market

thermal-interface-materials-market

qr-code-payment-market

agriculture-and-farm-equipment-market